Figure 6.

In vivo effects of inhibitor therapy on MEK1/2 signaling. Mice orthotopically implanted with patient-derived tumors 366 (A), 608 (B), and 738 (C) were treated for 24 hours with vehicle control, lapatinib (65 mg/kg, twice daily), trametinib (3 mg/kg, daily), or combination of lapatinib (65 mg/kg) and trametinib (3 mg/kg, daily) and then sacrificed. Whole tumor lysates from these animals were analyzed by Western blot analysis with the indicated antibodies. Each lane represents the tumor lysate of an individual experimental mouse exposed to the indicated treatment condition.